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Early Invasive Strategy and In-Hospital Survival Among Diabetics With
Non-ST-Elevation Acute Coronary Syndromes: A Contemporary
National Insight
Ahmed N. Mahmoud, MD;* Islam Y. Elgendy, MD;* Hend Mansoor, PharmD, MS; Xuerong Wen, PhD, MPH, MS; Mohammad K. Mojadidi,
MD; Anthony A. Bavry, MD, MPH; R. David Anderson, MD, MS
Background-—There are limited data on the merits of an early invasive strategy in diabetics with non-ST-elevation acute coronary
syndrome, with unclear inﬂuence of this strategy on survival. The aim of this study was to evaluate the in-hospital survival of
diabetics with non-ST-elevation acute coronary syndrome treated with an early invasive strategy compared with an initial
conservative strategy.
Methods and Results-—The National Inpatient Sample database, years 2012–2013, was queried for diabetics with a primary
diagnosis of non-ST-elevation acute coronary syndrome deﬁned as either non-ST-elevation myocardial infarction or unstable angina
(unstable angina). An early invasive strategy was deﬁned as coronary angiographyrevascularization within 48 hours of admission.
Propensity scores were used to assemble a cohort managed with either an early invasive or initial conservative strategy balanced
on >50 baseline characteristics and hospital presentations. Incidence of in-hospital mortality was compared in both groups. In a
cohort of 363 500 diabetics with non-ST-elevation acute coronary syndrome, 164 740 (45.3%) were treated with an early invasive
strategy. Propensity scoring matched 21 681 diabetics in both arms. Incidence of in-hospital mortality was lower with an early
invasive strategy in both the unadjusted (2.0% vs 4.8%; odds ratio [OR], 0.41; 95% CI, 0.39–0.42; P<0.0001) and propensity-
matched models (2.2% vs 3.8%; OR, 0.57; 95% CI, 0.50–0.63; P<0.0001). The beneﬁt was observed across various subgroups,
except for patients with unstable angina (Pinteraction=0.02).
Conclusions-—An early invasive strategy may be associated with a lower incidence of in-hospital mortality in patients with
diabetes. The beneﬁt of this strategy appears to be superior in patients presenting with non-ST-elevation myocardial infarction
compared with unstable angina. ( J Am Heart Assoc. 2017;6:e005369. DOI: 10.1161/JAHA.116.005369)
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D iabetes mellitus (DM) is a rapidly growing global healthburden. In 2014, the prevalence of DM was estimated to
be 422 million worldwide, doubling in frequency since 1980.1
In the United States, the prevalence of DM increased
dramatically from 3.5% in 1990 to 8.3% in 2012.2 DM is a
predominant risk factor for atherosclerotic coronary artery
disease (CAD) and acute myocardial infarction (MI).3,4
Diabetics have a higher incidence of multivessel CAD,
accelerated atherosclerosis, atherosclerotic plaque rupture,
and increased platelet activity, all of which increase the
incidence of acute MI compared to nondiabetics.4 Addition-
ally, DM is independently associated with a higher incidence
of early and late mortality following a non-ST-elevation acute
coronary syndrome (NSTE-ACS).5,6
There is currently a paucity of data on the beneﬁt of an
early invasive strategy in diabetic patients with NSTE-ACS,
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given the limited number of diabetic patients enrolled in most
randomized, clinical trials.7 Multiple observational studies and
meta-analyses of randomized trials demonstrate the beneﬁt of
an early invasive strategy in management of diabetic NSTE-
ACS patients, mainly through reduction of composite clinical
event rates and MI.8,9 As a direct consequence, the American
College of Cardiology Foundation/American Heart Associa-
tion (ACCF/AHA) Task Force recommends a routine invasive
strategy (within 72 hours of hospitalization) for diabetics
presenting with NSTE-ACS.10 However, evidence from real-life
registry data indicates that diabetics are less frequently
offered acute reperfusion therapy or acute revascularization
compared to nondiabetics.6,11,12
To date, there is insufﬁcient evidence to support a survival
beneﬁt of an early invasive strategy in diabetic patients with
NSTE-ACS. The aim of this study is to evaluate the effect of an
early invasive strategy in NSTE-ACS diabetic patients, with
emphasis on survival, length of hospital stay, and cost.
Methods
Study Data Sources
The National Inpatient Sample (NIS) database (years 2012 and
2013) was used to collect data for the current study. Years
2012 and 2013 were chosen because those were the most
recent NIS database releases at the time this study was
conducted and thus would most closely reﬂect contemporary
management of NSTE-ACS. In 2012, the NIS was redesigned to
include a random sample of patient discharges from all
hospitals, rather than a random sample of hospitals retaining
their discharges, which resulted in more-precise national
estimates. The NIS is the largest all-payer database in the
United States available for public use and sponsored by the
Agency for Healthcare Research and Quality (AHRQ) as a part of
the Healthcare Cost and Utilization Project.13 It represents a
20% stratiﬁed sample of all discharges from the US community
hospitals. Each individual patient hospitalization is de-identiﬁed
and maintained as a speciﬁc entry. Data available in the NIS
include 1 primary and 24 secondary diagnoses, 25 procedure
diagnoses (in International Classiﬁcation of Diseases, Ninth
Edition, Clinical Modiﬁcation [ICD-9-CM] coding format),
patient demographic characteristics (eg, sex, age, race, and
median household income), hospital characteristics (eg, own-
ership), expected payment source, total hospital charges,
discharge status, length of hospital stay, as well as, severity
and comorbidity measures. Discharge weights are also avail-
able for each patient’s record, which could be used in national
weighted estimates generation. This study was deemed to be
exempt from the Institutional Review Board (IRB) because of
the public nature of the NIS database, with the absence of any
personal identifying information.
Validation and Data Control
The NIS performs annual data quality assessments, to ensure
the internal validly of its data. It had been previously
compared with alternative databases, such as American
Hospital Association Annual Survey Database, the National
Hospital Discharge Survey from the National Center for Health
Statistics, and the Med-PAR inpatient database from Centers
for Medicare and Medicaid Services, with comparable
estimates to all of the previously stated databases.14
Patient Population
All patients with a primary diagnosis code of non-ST-elevation
myocardial infarction (NSTEMI) (ICD-9-CM code of 410.7x) or
unstable angina (UA; ICD-CM 9 code of 411.1) and secondary
diagnosis of diabetes mellitus (according to the Elixhauser
comorbidity software deﬁned by the AHRQ) were included.15
The analysis was limited to patients with the primary diagnosis
of NSTE-ACS as it is usually considered the main reason for
admission in the NIS database. This would allow the exclusion
of patients with type 2 NSTEMI secondary to other concomitant
diseases. An early invasive strategy group was deﬁned as
coronary angiography (ICD-9-CM codes of 88.55, 37.22, or
37.23) with or without revascularization, that is, percutaneous
coronary intervention (PCI; ICD-9-CM codes of 00.66, 36.01,
36.02, 36.05, 36.06, and 36.07) or coronary artery bypass
grafting (CABG; ICD-9-CM code 36.1x) with procedure time
being within 48 hours of admission (ie, day 0 or 1). The
remaining patients were deﬁned as an initial conservative
strategy group. This deﬁnition of an early invasive strategy in
NSTE-ACS has previously been used for other studies utilizing
data from the NIS database.16,17
Study Outcomes
The main outcome of this study was in-hospital mortality,
referred to in the NIS database as the “DIED” variable. The
main outcome was compared in both the early invasive and
initial conservative strategy groups after adjusting for multiple
patient and hospital characteristics. Other outcomes of
interest were length of hospital stay, referred in the NIS
database as “LOS” variable and total hospital charges,
referenced as the “TOTCHG” variable. The total hospital
charges represent the total amount billed by the hospital for
service rather than the actual payment received.
Patients and Hospital Characteristics
Data variables collected were patients’ demographics, includ-
ing age, sex, race, median household income by ZIP code,
weekend versus weekday admission, and primary expected
payer (Medicare, Medicaid, Private insurance, Uninsured, or
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Other) and the Elixhauser list of comorbidities. Other relevant
diagnoses were also extracted by their corresponding ICD-9-
CM codes, including acute ischemic stroke, intracranial
hemorrhage, gastrointestinal bleeding, cardiogenic shock,
family history of coronary artery disease (CAD), history of
past MI, past PCI or CABG, past stroke or transient ischemic
attack (TIA), CAD, carotid artery disease, smoking, dyslipi-
demia, atrial ﬁbrillation, and dementia. Hospital characteris-
tics, such as bed size (small, medium, and large), urban
location, and teaching status, were also collected.18 A full list
of ICD-9-CM codes for all variables collected in the current
study is supplied in Table 1.
Statistical Analysis
Weighted national estimates were calculated using the
discharge weights supplied by the NIS. Frequencies and
percentages were used for estimation of categorical patient
and hospital characteristics and means with SD or medians,
with 25th to 75th percentile ranges, for continuous ones.
Categorical variables were compared by Pearson’s chi-square
test, and an independent-sample Student t test was used for
means comparison in both groups. Medians were compared
using Mood’s median test. A multivariable logistic regression
model was constructed using all previously stated patient and
hospital characteristics as independent variables, with early
invasive strategy being the dependent variable. The resultant
individually matched probability score was then used for
propensity score matching of 2 similar groups (an early
invasive strategy vs initial conservative strategy) with 1:1 ratio
and match tolerance of 0.01. A clinically signiﬁcant difference
between both groups was considered present if the absolute
difference in frequency or means was >5% postmatching. The
propensity-matched cohort of patients was then used to
compare the incidence of different outcomes of interest. The
odds ratio (OR) of in-hospital mortality was calculated in the
propensity-matched data using a binary conditional logistic
regression model.
A subgroup analysis was conducted comparing the OR of
in-hospital mortality according to the use of an early invasive
strategy across various predeﬁned subsets, including
NSTEMI versus UA, history of congestive heart failure
(CHF), presence of cardiogenic shock, males versus females,
and past history of MI, CAD, or revascularization (PCI or
CABG). A secondary propensity adjusted multivariable logis-
tic regression analysis was also calculated for in-hospital
mortality with all previously stated variables along with the
use of early invasive strategy and the propensity score as
independent variables. The regression was performed by a
backward step-wise approach with a cut-off level of 0.05 for
entry and 0.1 for removal, followed by calculation of an
adjusted OR for in-hospital mortality.
To take into account the possibility of an immortality
time bias, a sensitivity analysis was conducted after
exclusion of NSTE-ACS patients who had a length of hospital
stay less than 48 hours (ie, day 0 and 1) in the propensity-
matched cohort. Immortal time bias refers to a period of
follow-up during which, by design, the study outcome cannot
occur.19 Limiting the analysis to patients, who had a length
of hospital stay more than 48 hours, was an indirect method
of analyzing patients who survived for at least 48 hours, as
the time of death was not a reported variable in the NIS
database.
Finally, another propensity score analysis was conducted
using a tighter match tolerance of 10e5 to conﬁrm the
ﬁndings of the primary analysis, because a statistically
signiﬁcant difference in the frequency of some categorical
variables was detected in the primary analysis. All statistical
analyses were performed using IBM SPSS Statistics software
(version 23.0; IBM Corp., Armonk, NY) with 2-sided P value of
<0.05 for statistical signiﬁcance assessment for all analyses
and OR with 95% CI as a measure of effect size reported by
logistic regression.
Table 1. International Classiﬁcation of Diseases, Ninth
Edition, Clinical Modiﬁcation (ICD-9-CM) Codes of the
Variables Included in the Propensity Score Matching*
Variable ICD-9-CM Code
Acute ischemic stroke 433.01, 433.11, 433.21, 433.31,
433.81433.91, 434.01, 434.11,
434.91, 435.x, 436
Intracranial hemorrhage 430, 431, 432.x
Gastrointestinal bleeding 153
Cardiogenic shock 785.51





CAD 414.00, 414.01, 414.02, 414.03, 414.04,
414.05, 414.06, 414.07
Carotid artery disease 433.10
Smoking history V15.82, 305.1
Dyslipidemia 53
Atrial fibrillation 427.31
Dementia 290.xx, 294.1x, 294.2x, 294.8,
331.0–331.12, 331.82, 797
CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; MI,
myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic
attack.
*Other variables not reported in the table were collected using Elixhauser Comorbidity
Software.15
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Results
Baseline Characteristics
We identiﬁed 363 500 diabetic patients who were admitted
in the United States with a primary diagnosis of NSTE-ACS
(mean age, 68.112.6 years; 42.9% female; 64.5% being
white; 65.5% covered by Medicare) during the years 2012–
2013. Most of the patients were hypertensive (82.8%) and
had a past history of CAD (77.9%). A total of 229 435
patients (63.1%) underwent an invasive strategy (early or
delayed) during their admission (coronary angiography, PCI,
or CABG). Of the total patient population, 164 740 patients
(45.3%) had an early invasive strategy performed during
their hospital stay. Total incidence of in-hospital mortality
was 12 925 patients (3.9%). Patient and hospital charac-
teristics of the included patients are summarized in
Table 2.
Compared with an initial conservative strategy, patients
undergoing an early invasive strategy were younger (65.2
[SD=11.8] vs 70.6 [SD=12.8] years; P<0.0001), less fre-
quently female (38.9% vs 46.3%; P<0.0001), and had fewer
comorbidities (Table 2). The use of an early invasive strategy
was more common in large-bed-size hospitals and in urban
teaching hospitals (Table 2). Patients carrying a diagnosis of
UA were less likely to undergo an early invasive strategy
compared to those with NSTEMI (21.3% vs 45.3%; P<0.0001).
The frequency of revascularization was higher in the early
invasive strategy group by both PCI (96.9% vs 30.1%;
P<0.0001) and CABG (15.6% vs 5.9%; P<0.0001) (Table 2).
Nonetheless, all patients in the initial conservative strategy
group who had a coronary angiography performed had a
revascularization procedure (i.e. PCI and/or CABG) as well.
Propensity score matching yielded 21 681 patients in both
groups with a similar distribution of patient and hospital
characteristics between the 2 groups of interest, except for a
few categorical variables such as expected primary payer
(P<0.0001), race (P<0.0001), median household income
(P=0.02), and hospital location (P<0.0001). However, all
variables had absolute frequency differences less than 5%
and thus deemed clinically insigniﬁcant (Table 2). To conﬁrm
our results, a secondary propensity score analysis was
constructed with a tighter match tolerance of 10e5 that
yielded 12 363 patients in the early invasive strategy group and
12 367 in the initial conservative approach group, matched in
all the formerly stated categorical variables (Table S1).
In-Hospital Mortality
The incidence of in-hospital mortality was lower with an early
invasive compared with an initial conservative strategy in the
unadjusted cohort (2.0% vs 4.8%; OR, 0.41; 95% CI, 0.39–
0.42; P<0.0001). This beneﬁt was maintained in the
propensity-matched cohort (2.2% vs 3.8%; OR, 0.57; 95% CI,
0.50–0.63; P<0.0001) and in the propensity-adjusted multi-
variable logistic regression analysis (OR, 0.54; 95% CI, 0.52–
0.57; P<0.0001; Figure 1). The incidence of in-hospital
mortality also was lower with an early invasive strategy in
the secondary post-hoc analysis using a tighter match
tolerance (2.5% vs 3.7%; OR, 0.65; 95% CI, 0.56–0.75;
P<0.0001) and in the sensitivity analysis after excluding the
patients with length of hospital stay less than 48 hours in the
propensity-matched cohort (2.1 vs 3.3; OR, 0.63; 95% CI,
0.56–0.72; P<0.0001).
On subgroup analysis, the beneﬁt of an early invasive
strategy was demonstrated among a wide range of prespec-
iﬁed subgroups except in patients with UA, where there was
no apparent evidence of survival beneﬁt with an early invasive
strategy (0.5% vs 0.1%; OR, 7.86; 95% CI, 0.82–75.72;
P=0.07), with evidence of heterogeneity when compared to
NSTEMI patients (Pinteraction=0.02; Figure 2).
Other Outcomes
An early invasive strategy was associated with a shorter
length of hospital stay compared with an initial conservative
strategy with a median of 3 (2–7) versus 4 days (2–7),
respectively (P<0.0001), and higher total hospital charges
with a median of 66 042 US dollars ($40315–112895) versus
39 265$ (19 193–77 832$), respectively (P<0.0001;
Figure 1).
Discussion
In the current propensity-matched analysis of contemporary
real-life data, an early invasive strategy was associated with
an increased in-hospital survival in NSTE-ACS patients with
concomitant DM. These results support the 2014 ACCF/AHA
guideline recommendations for an early invasive strategy in
diabetics, especially those with high-risk features (eg, NSTEMI
and cardiogenic shock).10 Meanwhile, the use of this strategy
in lower risk patients, such as those with UA, may not be
associated with improved survival.
The survival beneﬁt of an early invasive strategy in the
NSTE-ACS population remains a matter of ongoing debate.20–22
Whereas none of the landmark trials comparing an early
invasive with an initial conservative strategy illustrated a
statistically signiﬁcant reduction in mortality, these trials were
not statistically powered to answer that question.21–24 We
calculated the minimal sample size required by a randomized
trial to detect the difference in proportions illustrated in our
study and found that the sample size of almost 3500 patients
would be necessary to obtain the same results,25,26 which is
more than double the number of diabetic NSTE-ACS patients
DOI: 10.1161/JAHA.116.005369 Journal of the American Heart Association 4
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P Value*Early Invasive (%) Initial Conservative (%) Early Invasive (%) Initial Conservative (%)
Total number of patients 164 740 (100) 198 760 (100) 21 681 (100) 21 681 (100)
Primary diagnosis
NSTEMI† 161 020 (98) 185 055 (93) <0.0001 21 130 (98) 20 247 (93) <0.0001
UA† 3720 (2) 13 705 (7) <0.0001 550 (3) 1434 (7) <0.0001
Patient demographics
Age, mean y (SD) 65 (12) 71 (13) <0.0001 67 (11) 68 (13) 0.09
Female sex 64 130 (39) 91 945 (46) <0.0001 9044 (42) 9176 (42) 0.20
Race <0.0001 <0.0001*
White 109 040 (70) 128 515 (69) 15 063 (70) 14 983 (69)
Black 20 000 (13) 26 500 (14) 2768 (13) 3163 (15)
Hispanic 16 295 (10) 20 015 (11) 2227 (10) 2093 (10)
Asian or Pacific Islander 4400 (3) 5660 (3) 606 (3) 577 (3)
Other 6110 (4) 5655 (3) 868 (4) 710 (3)
Primary expected payer <0.0001 0.02*
Medicare 95 625 (58) 142 420 (72) 14 157 (65) 14 262 (66)
Medicaid 12 845 (8) 14 590 (7) 1477 (7) 1798 (8)
Private insurance 39 630 (24) 28 845 (14) 4327 (20) 3902 (18)
Uninsured 10 160 (6) 7390 (3) 1037 (5) 1075 (5)
Other 5110 (3) 4565 (2) 581 (3) 554 (3)
Weekend admission 33 325 (20) 59 330 (30) <0.0001 5279 (24) 5379 (25) 0.27
Household income (median) <0.0001 <0.0001*
0 to 25th percentile 53 420 (33) 66 370 (34) 7384 (34) 7280 (34)
26 to 50th percentile 43 660 (27) 51 265 (26) 5821 (27) 5668 (26)
51 to 75th percentile 36 995 (23) 43 555 (23) 4895 (23) 4921 (23)
76 to 100th percentile 27 175 (17) 32 760 (17) 3581 (17) 3812 (18)
Patient characteristics
Smoking 54 065 (33) 44 355 (22) <0.0001 6067 (28) 5901 (27) 0.08
Dyslipidemia 125 075 (76) 131 195 (66) <0.0001 15 786 (73) 15 666 (72) 0.20
Obesity 45 060 (27) 43 055 (21) <0.0001 5449 (25) 5369 (25) 0.38
Known history of CAD 146 755 (89) 136 395 (69) <0.0001 18 399 (85) 18 493 (85) 0.21
Family history of CAD 13 100 (8) 7365 (4) <0.0001 1148 (5) 1115 (5) 0.48
Past MI 20 705 (13) 25 895 (13) <0.0001 2922 (14) 3011 (14) 0.21
Past PCI 137 975 (84) 172 170 (87) <0.0001 3519 (16) 3548 (16) 0.71
Past CABG 12 640 (8) 24 895 (13) <0.0001 2178 (10) 2269 (11) 0.15
Past stroke or TIA 9150 (6) 13 390 (7) <0.0001 1316 (6) 1321 (6) 0.92
Carotid artery disease 4080 (3) 4750 (2) 0.09 573 (3) 575 (3) 0.95
Peripheral vascular disease 25 335 (15) 36 090 (18) <0.0001 3819 (18) 3817 (18) 0.98
Pulmonary circulation disease 145 (<1) 275 (<1) <0.0001 21 (<1) 29 (<1) 0.26
Dementia 3000 (2) 15 350 (8) <0.0001 562 (3) 508 (2) 0.10
Atrial fibrillation 22 725 (14) 39 970 (20) <0.0001 3536 (16) 3578 (17) 0.59
Alcohol abuse 3525 (2) 3830 (2) <0.0001 454 (2) 434 (2) 0.50
Deficiency anemia 32 325 (20) 55 310 (28) <0.0001 5062 (23) 5101 (24) 0.66
Continued
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P Value*Early Invasive (%) Initial Conservative (%) Early Invasive (%) Initial Conservative (%)
Collagen vascular disease 3505 (2) 4410 (2) 0.06 480 (2) 471 (2) 0.79
Chronic blood loss anemia 1295 (1) 2085 (1) <0.0001 197 (1) 200 (1) 0.88
Congestive heart failure 690 (<1) 2005 (1) <0.0001 124 (<1) 145 (<1) 0.20
Valvular disease 195 (<1) 615 (<1) <0.0001 36 (<1) 47 (<1) 0.23
Chronic pulmonary disease 35 540 (22) 52 430 (26) <0.0001 5252 (24) 5322 (25) 0.43
Coagulopathy 9480 (6) 11 610 (6) 0.27 1313 (6) 1280 (6) 0.50
Liver disease 2895 (2) 4385 (2) <0.0001 420 (2) 416 (2) 0.89
Renal disease (chronic) 41 815 (25) 78 900 (40) <0.0001 6967 (32) 7005 (32) 0.70
Electrolytes abnormalities 34 070 (21) 56 890 (29) <0.0001 5170 (24) 5203 (24) 0.71
AIDS 120 (<1) 175 (<1) 0.12 16 (<1) 14 (<1) 0.72
Drug abuse 3050 (2) 3425 (2) <0.0001 392 (2) 394 (2) 0.94
Depression 14 495 (9) 19 320 (10) <0.0001 1971 (9) 2040 (9) 0.25
Hypertension 138 115 (84) 162 920 (82) <0.0001 18 088 (83) 18 086 (83) 0.98
Hypothyroidism 19 215 (12) 29 180 (15) <0.0001 2801 (13) 2819 (13) 0.80
Lymphoma 705 (<1) 1240 (0.6) <0.0001 110 (<1) 114 (<1) 0.79
Metastatic cancer 625 (<1) 2050 (1) <0.0001 114 (<1) 106 (<1) 0.59
Solid tumor without metastasis 1720 (1) 3480 (2) <0.0001 289 (1) 295 (1) 0.80
Other neurological disorder 7385 (5) 16 065 (8) <0.0001 1142 (5) 1192 (6) 0.29
Paralysis 2735 (2) 5445 (3) <0.0001 431 (2) 457 (2) 0.38
Psychoses 4040 (3) 6860 (4) <0.0001 622 (3) 597 (3) 0.47
Peptic ulcer (nonbleeding) 35 (<1) 35 (<1) 0.43 4 (<1) 2 (<1) 0.41
Weight loss 3330 (2) 6725 (3) <0.0001 542 (3) 518 (2) 0.46
Cardiogenic shock 6100 (4) 5220 (3) <0.0001 678 (3) 654 (3) 0.50
Intracranial hemorrhage 150 (<1) 255 (<1) <0.0001 21 (<1) 24 (<1) 0.66
Acute ischemic stroke 2315 (1) 3185 (2) <0.0001 328 (2) 337 (2) 0.73
Gastrointestinal bleeding 2545 (2) 5530 (3) <0.0001 433 (2) 455 (2) 0.46
Invasive procedure
PCI† 159 585 (97) 59 810 (30) <0.0001 10 415 (48) 3862 (18) <0.0001
CABG† 25 650 (16) 11 760 (6) <0.0001 3037 (14) 1820 (8) <0.0001
Hospital characteristics
Hospital bed size <0.0001 0.05
Small 13 150 (8) 26 530 (13) 2062 (10) 2203 (10)
Medium 40 040 (24) 54 740 (28) 5568 (26) 5553 (26)
Large 111 550 (68) 117 490 (59) 14 051 (65) 13 925 (64)
Hospital location <0.0001 0.14
Urban teaching 92 320 (56) 91 430 (46) 11 133 (51) 11 532 (53)
Urban nonteaching 61 130 (37) 81 580 (41) 8811 (41) 8213 (38)
Rural 11 290 (7) 25 750 (13) 1737 (8) 1936 (9)
In-hospital mortality 3320 (2.0) 9605 (4.8) <0.0001 475 (2.2) 826 (3.8) <0.0001
All percentages are approximated to the nearest integer. AIDS indicates acquired immune deﬁciency syndrome; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease;
NSTEMI, non-ST-elevation myocardial infarction; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; UA, unstable angina.
*Although P value is signiﬁcant the difference in % between both arms was <5% and thus deemed clinically nonsigniﬁcant.
†
Variables were not included in the propensity score matching.
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included in all previous trials combined.9 Although our results
suggest an association between an early invasive strategy and
improved survival in diabetics with NSTE-ACS, this does not
establish causality, given the retrospective nature of the data;
thus, larger randomized, clinical trials powered for differen-
tiation between short- and long-term mortality are necessary
to conﬁrm our ﬁndings.
Earlier meta-analyses of randomized trials have demon-
strated a possible reduction in all-cause mortality following an
early invasive strategy, with a mean follow-up of 1.5 to
2 years after the initial event.20,22 However, subsequent
meta-analyses failed to replicate the same results.7,27 A meta-
analysis of 9904 patients with NSTE-ACS from 9 randomized
trials investigated the beneﬁt of an early invasive strategy use
in diabetics (17% of the total population) compared to
nondiabetics.9 Although the study did not show any added
mortality beneﬁt with an early invasive strategy, it showed a
reduction in the rate of nonfatal MI.9
Interestingly, the beneﬁt of an early invasive strategy was
least evident in the subgroup of diabetics diagnosed primarily
with UA. This is consistent with previous evidence showing a
lack of beneﬁt of an early invasive strategy in low-risk NSTE-
ACS patients with low troponin levels28 and supports
choosing an initial conservative strategy as a valid option in
this subset of patients. Another ﬁnding was the infrequent use
of an early invasive strategy in high-risk diabetic patients
admitted with NSTE-ACS and cardiogenic shock. Only, 54% of
the patients with cardiogenic shock underwent an early
invasive strategy, however, those patients were the ones who
beneﬁted the most from this strategy with the lowest odds of
in-hospital mortality compared with both conservatively
managed cardiogenic shock patients and noncardiogenic
shock patients managed by an early invasive strategy.
A signiﬁcant effect modiﬁcation inﬂuenced by the admission
day was evident, with less beneﬁt noted with an early invasive
strategy, if the patients were admitted during weekends
compared with weekdays (Pinteraction=0.02). Although the exact
reasons for such differences are not entirely clear, it may be
attributed to lack of a readily available catheterization staff
together with some human factors, such as sleep deprivation
and fatigue as observed in previous studies.29 Despite this, the
incidence of in-hospital mortality remained signiﬁcantly lower
with an early invasive strategy when compared with an initial
conservative strategy during the weekends (OR=0.71; 95% CI,
0.57–0.90; P<0.0001).
Even though a routine invasive strategy is recommended
for diabetics by major cardiovascular guideline commit-
tees,10,30 national registries worldwide have illustrated that
this strategy is still underutilized.6,10 Although the exact
explanation for this ﬁnding is unclear, our analysis indicates
that an early invasive strategy was used more frequently in
younger patients with less comorbidity at baseline, which is
usually not the case in most diabetics at the time of NSTE-
ACS presentation.
Although the deﬁnition of timing for an early invasive
strategy (ie, within 48 hours) appears to be somewhat
Figure 1. A cluster column graph comparing all outcomes of interest between an early invasive and an
initial conservative strategy. LOS, length of hospital stay; $, US dollars.
Both length of hospital stay and total hospital charges were derived from the propensity-matched cohort of
patients.
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different in the current study compared with the ACC/AHA
guidelines, the same deﬁnition was adopted by the pivotal
trials comparing an early invasive strategy to an initial
conservative strategy, such as Treat Angina with Aggrastat
and Determine Cost of Therapy with an Invasive or Conser-
vative Strategy—Thrombolysis in Myocardial Infarction 18
(TACTICS-TIMI 18; 4–48 hours),31 Invasive versus Conserva-
tive Treatment in Unstable Coronary Syndromes (ICTUS;
24–48 hours)21 and FRagmin and Fast Revascularisation
during InStability in Coronary artery disease II (FRISC II;
24–48 hours)23 trials. A procedure time of 24 hours was used
mainly to deﬁne an early invasive strategy in trials comparing
early with delayed invasive strategy.32 Thus, we preferred to
use the 48-hour deﬁnition of an early invasive strategy to be
consistent with previous trials comparing early invasive to
initial conservative strategies in NSTE-ACS patients.
To our knowledge, this study represents the largest
contemporary analysis comparing an early invasive with an
initial conservative strategy in diabetics with NSTE-ACS.
Although the NIS is an administrative database, the large
sample size of patients that allowed adequate power to
assess the main outcome of interest, together with the
diverse demographics of the included patients, large number
of patients’ and hospital characteristics, and various in-
hospital complications recorded, made this database an
excellent source to explore our question of interest. Multiple
similar trend and outcome studies have been published using
the NIS database, which validates its reliability in addressing
various practice issues.14,16,17,33 Despite these strengths, the
current study has some limitations.
First, although we adjusted for over 50 independent
variables in the propensity-matched analysis, the current
study is retrospective in nature and is subject to biases
attributed to unmeasured confounders. Second, the inherent
limitation of the NIS database, such as error in coding or
misdiagnosis, may have occurred; however, given the large
Figure 2. Forest plot representing subgroup analysis of in-hospital mortality according to various patient risk factors. ACS indicates acute
coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; MI, myocardial infarction;
NSTEMI, non-ST-elevation myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention.
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patient sample, we believe that such errors would be limited
and should not affect the integrity of our results. Also, the NIS
is an administrative database that relies mainly on ICD-9
codes rather than clinically adjudicated outcomes or diag-
noses. Third, because of the administrative nature of the NIS
database, multiple clinical data were not accounted for, such
as medications administered (eg, antiplatelet and -coagulant
therapy), laboratory (eg, troponins and brain natriuretic
peptide levels), and imaging (eg, echocardiography) results.
This limited the ability to assess the merits of an early
invasive strategy in various risk subgroups (eg, according to
the Thrombolysis in Myocardial Infarction [TIMI] score). We
attempted to assess the impact of past CAD and past
revascularization history in our subgroup analysis as an
indirect assessment of patients with higher TIMI score, and
there was no evidence of effect modiﬁcation by either. Lack
of data regarding various types of medications administered
is an important limitation, given that the inability to admin-
ister certain medications (eg, anticoagulant and -platelet
agents) that are known to improve survival in NSTE-ACS,
because of the patients’ underlying comorbidities, might have
affected the choice of initial treatment strategy. Fourth, the
individual subgroup analysis comparisons were not propensity
matched, and thus the possibility of unmeasured bias cannot
be excluded. Finally, given the nature of NIS data, we were
limited to in-hospital mortality and could not compare both
strategies with regard to long-term outcomes.
Conclusions
In this large propensity score matched analysis, an early
invasive strategy was found to be associated with improved in-
hospital survival in diabetic patients, especially those with high-
risk features, such as NSTEMI or cardiogenic shock. The use of
an early invasive strategy in diabetics with UA does not appear
to be beneﬁcial with a possible signal of harm, and thus an initial
conservative strategy may be a safer approach for these
patients. Our ﬁndings should be conﬁrmedwith future trials that
are powered for detection of short- and long-term survival
beneﬁt of an early invasive strategy in diabetics with NSTE-ACS.
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Table S1. Patient and hospital characteristics of the post-hoc propensity matched cohort of patients 
with lower match tolerance.  
Variable (%) 
Propensity-score matched P-value  
Early invasive  
(%) 
Initial conservative  
(%) 
Number of patients 12,363(100) 12,367(100)  
Patient demographics    
Age, mean years (SD) 67.6(11) 67.7(12) 0.47 
Female sex 5,122(41) 5,271(41) 0.06 
Race   0.60 
White 8,523(69) 8,543(69)  
Black 1,652(14) 1,690(13)  
Hispanic 1,321(11) 1,284(10)  
Asian or Pacific Islander 350(3) 333(3)  
Other 427(4) 419(3)  
Primary expected payer   0.13 
Medicare 8,076(65) 8,173(66)  
Medicaid 960(8) 985(8)  
Private insurance 2,278(18) 2,237(18)  
Uninsured 662(5) 586(5)  
Other 326(3) 333(3)  
Weekend admission 3,064(25) 3,026(25) 0.58 
Household income (median)   0.66 
0-25th percentile 4,229(34) 4,229(34)  
26-50th percentile 3,248(26) 3,239(26)  
51-75th percentile 2,812(23) 2,761(22)  
76-100th percentile 2,074(17) 2,138(17)  
Patient characteristics    
Smoking 3,450(28) 3,366(27) 0.23 
Dyslipidemia 8,919(72) 8,905(72) 0.81 
    
Obesity 3,182(26) 3,103(25) 0.24 
Known history of CAD 10,365(84) 10,527(85) 0.01 
Family history of CAD 631(5) 624(5) 0.84 
Prior myocardial infarction 1,668(14) 1,719(14) 0.57 
Prior PCI 2,021(16) 2,034(16) 0.83 
Prior CABG 1,251(10) 1,251(10) 0.99 
Prior stroke or TIA 750(6) 730(6) 0.73 
Carotid artery disease 325(3) 328(3) 0.91 
Peripheral vascular disease 2,161(18) 2,231(18) 0.20 
Pulmonary circulation disease 15(<1) 13(<1) 0.71 
Dementia 353(3) 304(3) 0.05 
Atrial fibrillation 2,027(16) 2,034(16) 0.91 
Alcohol abuse 259(2) 260(2) 0.97 
Deficiency anemia 2,936(24) 2,976(24) 0.56 
Collagen vascular disease 254(2) 271(2) 0.46 
Chronic blood loss anemia 116(1) 126(1) 0.52 
Congestive heart failure 68(<1) 81(<1) 0.29 
Valvular disease 15(<1) 20(<1) 0.40 
Chronic pulmonary disease 3,013(24) 3,044(25) 0.66 
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Liver disease 236(2) 243(2) 0.75 
Renal disease (chronic) 4,006(32) 4,044(33) 0.62 
Electrolytes abnormalities 3,006(24) 3,030(25) 0.73 
AIDS 11(<1) 9(<1) 0.65 
Drug abuse 232(2) 225(2) 0.74 
Depression 1,156(9) 1,154(9) 0.96 
Hypertension 10,373(84) 10,290(83) 0.14 
Hypothyroidism 1,579(13) 1,618(13) 0.47 
Lymphoma 60(<1) 67(<1) 0.54 
Metastatic cancer 60(<1) 74(<1) 0.23 
    
Solid tumor without metastasis 165(1) 148(1) 0.33 
Other neurological disorder 698(6) 679(6) 0.59 
Paralysis 236(2) 250(2) 0.52 
Psychoses 359(3) 334(3) 0.33 
Peptic ulcer (non-bleeding) 1(<1) 1(<1) 1.00 
Weight loss 317(3) 327(3) 0.69 
Cardiogenic shock 400(3) 374(3) 0.34 
Intra-cranial hemorrhage 9(<1) 15(<1) 0.22 
Acute ischemic stroke 194(2) 182(2) 0.53 
Gastrointestinal bleeding 245(2) 238(2) 0.75 
Hospital characteristics    
Hospital bed size   0.25 
Small 1,161(9) 1,238(10)  
Medium 3,178(26) 3,176(26)  
Large 8,024(65) 7,953(64)  
Hospital location   0.21 
Urban teaching 6,309(49) 6,453(50)  
Urban non-teaching 5,033(41) 4,877(39)  
Rural 1,021(8) 1,037(8)  
In-hospital mortality 303(2.5) 462(3.7) <0.0001 
 
All percentages are approximated to the nearest integer. 
CAD= coronary artery disease, PCI= percutaneous coronary intervention, CABG= coronary artery bypass graft 
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